COMPANY

AvenCell Therapeutics

HQ: Watertown, MA source · avencell.com ↗

Location: Watertown, MA · source · Oct 14, 2026

Profile checked Oct 10, 2026

Keywords: Lymphoma Diffuse Large B-cell Leukemia Relapse Lymphoma Receiving CAR-T Therapy B-cell Lymphoma Chronic Lymphocytic Leukemia Hematologic Malignancy AML (Acute Myelogenous Leukemia) Prostate Cancer Allo-QuadCAR01-T

2Trials (company is sponsor)

Timeline

Jan 29, 2026 Trial start —: Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials source ↗
Jan 6, 2026 Trial start Phase 1/Phase 2: Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies source ↗

Upcoming milestones

Apr 27, 2029 (ESTIMATED) · Phase 1/Phase 2 · Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies · NCT07284433
Nov 30, 2040 (ESTIMATED) · · Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials · NCT07474051

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT07284433	Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies	Phase 1/Phase 2	Recruiting	Jan 6, 2026	Apr 27, 2029 (estimated)
NCT07474051	Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials	Not listed	Enrolling by invitation	Jan 29, 2026	Nov 30, 2040 (estimated)